eFFECTOR Therapeutics, Inc. (EFTR): Price and Financial Metrics
GET POWR RATINGS... FREE!
EFTR Stock Price Chart Interactive Chart >
EFTR Price/Volume Stats
| Current price | $1.76 | 52-week high | $40.42 |
| Prev. close | $1.79 | 52-week low | $1.65 |
| Day low | $1.69 | Volume | 26,800 |
| Day high | $1.85 | Avg. volume | 31,061 |
| 50-day MA | $3.56 | Dividend yield | N/A |
| 200-day MA | $8.12 | Market Cap | 72.85M |
eFFECTOR Therapeutics, Inc. (EFTR) Company Bio
eFFECTOR Therapeutics, Inc., a biotechnology company, develops selective translation regulators for the treatment of cancer and other serious diseases. It focuses on small molecule drugs that act by selectively regulating translation that is known as protein synthesis. The company was incorporated in 2012 and is based in San Diego, California.
Latest EFTR News From Around the Web
Below are the latest news stories about eFFECTOR Therapeutics Inc that investors may wish to consider to help them evaluate EFTR as an investment opportunity.
eFFECTOR Appoints Kristen Harrington-Smith to Board of DirectorsSAN DIEGO and REDWOOD CITY, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced the appointment of Kristen Harrington-Smith, Senior Vice President & Chief Commercial Officer at ImmunoGen, to the company’s board of directors. Concurrent with Ms. Harrington-Smith’s appointment, Jonathan Root, M.D., has resigned from the company’s board of direct |
These 2 Stocks Could Be Bought Out, Says Credit SuisseThe economy continues to recover from the pandemic impact, but the currents are flowing in multiple directions at once. Emblematic of the situation is the combination of high inflation and improving jobs numbers, each tugging in opposite directions on the economy. Still, there are some unequivocal signs of economic health that investors can latch onto. One of these, a boost in buyout activity, presents a particularly interesting set of data. In 2021, the US economy saw buyout transactions worth a total of $2.5 trillion, more than 25% higher than the previous record, 2015’s $1.96 trillion. |
2 ‘Strong Buy’ Stocks That Could Be Bought Out, According to Credit SuisseThe economy continues to recover from the pandemic impact, but the currents are flowing in multiple directions at once. Emblematic of the situation is the combination of high inflation and improving jobs numbers, each tugging in opposite directions on the economy. Still, there are some unequivocal signs of economic health that investors can latch onto. One of these, a boost in buyout activity, presents a particularly interesting set of data. In 2021, the US economy saw buyout transactions worth |
eFFECTOR Therapeutics to Present at 2022 BIO CEO & Investor ConferenceSAN DIEGO and REDWOOD CITY, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a biopharmaceutical company focused on pioneering the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that the Company will present and host 1x1 meetings at the 2022 BIO CEO & Investor Conference. Steve Worland, Ph.D., President and Chief Executive Officer of eFFECTOR, will provide an overview of the Company’s clinical developm |
eFFECTOR Therapeutics provides pipeline update; inks up to $50M investment contracteFFECTOR Therapeutics (EFTR) announced pipeline updates and an investment agreement with Lincoln Park Capital for a commitment of up to $50M over 36 months.The company said that a |
EFTR Price Returns
| 1-mo | N/A |
| 3-mo | -63.03% |
| 6-mo | -78.14% |
| 1-year | -81.93% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -78.74% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...